Results 151 to 160 of about 20,887 (223)

¹⁸F-FDG PET/MRI Multiparametric Imaging Features for Predicting MYCN Amplification Status in Children With High-Risk Neuroblastoma. [PDF]

Rev Neurol
Liang J, Li F, Ding Z, Yan B, Zhu Y, Wang F, Xuan W.   +6 more
europepmc   +1 more source

Epigenetic Liquid Biopsy Enables Universal Mutation-Agnostic Molecular Surveillance for High-Risk Neuroblastoma. [PDF]

Clin Cancer Res
Gal-Mark N, Grunwald A, Gahramanov V, Hameiri-Grossman M, Shinderman-Maman E, Gaas D, Shichrur K, Mordoukh J, Oniashvili N, Chausky Barzakh E, Sever A, Amar S, Ash S, Birger Y, Izraeli S, Ebenstein Y, Berko ER.   +16 more
europepmc   +1 more source

Investigating the spliceosome-MYCN interaction in neuroblastoma

Neuroblastoma (NB) is a childhood cancer originating from the peripheral nervous system. While low and intermediate risk cases classically have favourable prognosis, cases classified as high-risk will have a 5-year overall survival of 50% and a high ...
Lee, Onn
core  

Artificial Intelligence for Diagnosis, Risk Stratification, and Prognosis of Neuroblastoma - A Systematic Review and Meta-Analysis. [PDF]

Curr Oncol Rep
Serbena DR, Cieslack ILF, Ratis RC, Chaves DVP, de Oliveira Filho SS, Neves H, Dos Santos FS, Cassar DR, da Silva WC, Bonini JS.   +9 more
europepmc   +1 more source

p53 is a direct transcriptional target of MYCN in neuroblastoma

MYCN amplification occurs in approximately 25% of neuroblastomas, where it is associated with rapid tumor progression and poor prognosis. MYCN plays a paradoxical role in driving cellular proliferation and inducing apoptosis.
Tweddle DA, Gherardi S, Lunec J, Chen L, Wood KM, Iraci N, Perini G, Gamble LD   +7 more
core  

Multi‑omics identification of MSI2 as a super-enhancer‑driven vulnerability in MYCN‑amplified neuroblastoma. [PDF]

J Transl Med
Zhang X, Yang Y, Zhang M, Fan K, Huang Z, Zhang Y, Kong L, Chen Q, Tan R, Zhang S, Yu D, Xiong X, Wu K.   +12 more
europepmc   +1 more source

ATRX large deletions and truncating mutations are associated with primary induction chemotherapy resistance in high-risk neuroblastoma: a multicenter propensity-weighted cohort study. [PDF]

Front Oncol
Sun J, Qian B, Lu L, Zhou J.
europepmc   +1 more source

MYCN Amplification Drives Ferroptosis Susceptibility via Cysteine Metabolism in Retinoblastoma. [PDF]

Invest Ophthalmol Vis Sci
Chen Y, Xu H, Xiao L, Zhang Y, Gao Y, Man S, Wang D, Mou K, Huang Y, Yan N, Zhang M.   +10 more
europepmc   +1 more source

Overactivation of SHH signaling induces a cascade of dedifferentiation and oncogenesis in a new mouse model for choroid plexus carcinoma. [PDF]

Acta Neuropathol Commun
Peter LS, Altendorf L, Hack K, Thaden V, Göbel C, Mahnke B, Krebs C, Jauch-Speer SL, Kordes UR, Obrecht-Sturm D, Thomas C, Schüller U, Schoof M.   +12 more
europepmc   +1 more source

Correction: An unexpected role for caspase-2 in neuroblastoma. [PDF]

Cell Death Dis
Dorstyn L, Puccini J, Nikolic A, Shalini S, Wilson CH, Norris MD, Haber M, Kumar S.   +7 more
europepmc   +1 more source